Often, nodules improve with voice therapy and behavior modifications alone
0.6% of wild.type activtiy Y165H mutation identified in a in patient with classic galactosemia E203K - native heterozygous mutant, reduced activity by about 50% in erythrocytes E291K - site-directed mutagenesis for construction of the naturally occuring mutation, 62.8% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose E340X/L218L/N314D - native mutant, no or nearly no enzyme activity, L218L is a silent mutation, galactosemia phenotype F171L - site-directed mutagenesis, 10fold decreased activity F171W - site-directed mutagenesis, severely reduced abundance F171Y - site-directed mutagenesis, 4% activity compared to wild-type, no inhibition by excess UDP-glucose K285N - site-directed mutagenesis for construction of the naturally occuring mutation, below 0.2% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose L139P - site-directed mutagenesis for construction of the naturally occuring mutation, 1.9% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose L218L/N314D - native Duarte-1 D1 variant, L218L is a silent mutation, N314D leads to 110-130% activity compared to the wild-type N314D/E203K - homozygous N314D mutant with introduced cis mutation E203K does no longer show the reduced, but the full activity and increased thermolablity of mutant without E203K P183T - site-directed mutagenesis for construction of the naturally occuring mutation, 45.2% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose P185A - site-directed mutagenesis, reduced activity and reduced expression level compared to wild-type P185C - site-directed mutagenesis, no remaining activity, same expression level compared to wild-type P185D - site-directed mutagenesis, no remaining activity, same expression level compared to wild-type P185E - site-directed mutagenesis, reduced activity, same expression level compared to wild-type P185F - site-directed mutagenesis, no remaining activity, highly reduced expression level compared to wild-type P185G - site-directed mutagenesis, reduced activity and expression level compared to wild-type P185H - site-directed mutagenesis, no remaining activity, reduced expression level compared to wild-type P185I - site-directed mutagenesis, no remaining activity, highly reduced expression level compared to wild-type P185K - site-directed mutagenesis, no remaining activity, reduced expression level compared to wild-type P185L - site-directed mutagenesis, no remaining activity, highly reduced expression level compared to wild-type P185M - site-directed mutagenesis, no remaining activity, reduced expression level compared to wild-type P185N - site-directed mutagenesis, no remaining activity, reduced expression level compared to wild-type P185Q - site-directed mutagenesis, reduced activity, increased expression level compared to wild-type P185R - site-directed mutagenesis, no remaining activity, same expression level compared to wild-type P185S - site-directed mutagenesis, reduced activity, reduced expression level compared to wild-type P185T - site-directed mutagenesis, no remaining activity, reduced expression level compared to wild-type P185V - site-directed mutagenesis, no remaining activity, highly reduced expression level compared to wild-type P185W - site-directed mutagenesis, no remaining activity, highly reduced expression level compared to wild-type P185Y - site-directed mutagenesis, no remaining activity, reduced expression level compared to wild-type Q188N - site-directed mutagenesis, reduced activity R201H - site-directed mutagenesis for construction of the naturally occuring mutation, 62.8% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose R231H - site-directed mutagenesis for construction of the naturally occuring mutation, below 0.2% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose R258C - native mutant, 15-20% activity compared to wild-type, some clinical symptoms R259W - site-directed mutagenesis for construction of the naturally occuring mutation, below 0.2% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose R333G - native mutant, 20% activity compared to wild-type, no clinical symptoms R67C - site-directed mutagenesis for construction of the naturally occuring mutation, 2.3% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose T350A - site-directed mutagenesis for construction of the naturally occuring mutation, 9.9% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose V151A - site-directed mutagenesis for construction of the naturally occuring mutation, 4.6% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucosey W316X/N314D/G1105C/G1391A - native mutant, nearly no enzyme activity, galactosemia phenotype Y323D - site-directed mutagenesis for construction of the naturally occuring mutation, 9.6% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose 44 - t1/2: 2 min, 2 mg/ml serum albumin stabilizes considerably 48 - t1/2: 1 min, 2 mg/ml serum albumin stabilizes considerably 50 - 15 min, 30% loss of activity for the wild-type enzyme, over 55% loss of activity for the homozygous N314D mutant additional information - increased thermal lability of the mutant N314D compared to the wild-type dithioerythritol stabilizes during purification - freeze-thawing inactivates purified enzyme - freezing of dilute enzyme solution inactivates, concentration procedures lead to considerable loss of activity - sulfhydryl reagents restore activity of partially denatured enzyme and protect against inactivation - UDP-glucose stabilizes during gel filtration - -20C, partially purified, 10% loss of activity per month - 0C, 10% loss of activity per week - 0C, purified enzyme, 10% loss of activity within 2 weeks - 0C, purified in the presence of dithioerythritol, 2 weeks - 4C, adsorbed to DEAE-cellulose, about 2 months - freezing inactivates purified enzyme - 70600fold from erythrocytes - His-tagged recombinant wild-type and mutants F171Y and F171L to near homogeneity - partial from erythrocyte, several isozymes - placental enzyme to homogeneity, coelutes with a 67 kDa glycoprotein - recombinant His-tagged wild-type and mutant S135L from yeast, to near homogeneity - recombinant His-tagged wild-type and mutants P185A, P185S, P185G, P185E, and P185Q to near homogeneity - recombinant His-tagged wild-type, partial 67fold, and mutants from Escherichia coli Bl21(DE3) - tagged mutant heterodimers from yeast - expression in Sacchaormyces cerevisiae cloning in Escherichia coli and coexpression in yeast of mutant heterodimers derived from galactosemic patients, use of different tags - expression as fusion protein with glutathione-S-transferase from Schistosoma japonicum in a bacterial expression system - expression of His- and 12CA5 epitope-tagged subunits of mutants R333W and Q188R in yeast, analysis of homo- and heterodimer formation of wild-type and mutant subunits - expression of N314D mutants in human lymphoblasts - expression of wild-type and mutants as His-tagged proteins in Escherichia coli Bl21(DE3) - expression of wild-type and mutants in Saccharomyces cerevisiae - expression of wild-type and mutants in yeast - overexpression of wild-type and mutant S135L as His-tagged proteins, 2fold lower expression than the wild-type, in a null-background yeast - the GALT gene is located on chromosome 9p13 - diagnostics - the enzyme activity is measured for determination of galactosaemia using erythrocyte from blood samples, HPLC-based method development, overview drug development - the enzyme might be a target for inhibitor design in galactosemia treatment Mayes, J.S
CrossRef Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis Sarina Ailawadi, Jennifer E
Tsalic M, Bar-Sela G, Beny A, Visel B, Haim N (2003) Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients
MMP-9 is a substance that is secreted in the body and is found in the central nervous system, extracellular matrix, and serum
The traditional medical model measures Thyroid Stimulating Hormone (TSH) to assess thyroid dysfunction
